Comparison of RISK-PCI, GRACE, TIMI risk scores for prediction of major adverse cardiac events in patients with acute coronary syndrome

Aim To compare the prognostic performance of three major risk scoring systems including global registry for acute coronary events (GRACE), thrombolysis in myocardial infarction (TIMI), and prediction of 30-day major adverse cardiovascular events after primary percutaneous coronary intervention (RISK-PCI).

Methods This single-center retrospective study involved 200 patients with acute coronary syndrome (ACS) who underwent invasive diagnostic approach, ie, coronary angiography and myocardial revascularization if appropriate, in the period from January 2014 to July 2014. The GRACE, TIMI, and RISK-PCI risk scores were compared for their predictive ability. The primary endpoint was a composite 30-day major adverse cardiovascular event (MACE), which included death, urgent target-vessel revascularization (TVR), stroke, and non-fatal recurrent myocardial infarction (REMI).

Results The c-statistics of the tested scores for 30-day MACE or area under the receiver operating characteristic curve (AUC) with confidence intervals (CI) were as follows: RISK-PCI (AUC = 0.94; 95% CI 1.790-2.353), the GRACE score on admission (AUC = 0.73; 95% CI 1.013-1.045), the GRACE score on discharge (AUC = 0.65; 95% CI 0.999-1.033). The RISK-PCI score was the only score that could predict TVR (AUC = 0.91; 95% CI 1.392-2.882). The RISK-PCI scoring system showed an excellent discriminative potential for 30-day death (AUC = 0.96; 95% CI 1.339-3.548) in comparison with the GRACE scores on admission (AUC = 0.88; 95% CI 1.018-1.072) and on discharge (AUC = 0.78; 95% CI 1.000-1.058).

Conclusions In comparison with the GRACE and TIMI scores, RISK-PCI score showed a non-inferior ability to predict 30-day MACE and death in ACS patients. Moreover, RISK-PCI was the only scoring system that could predict recurrent ischemia requiring TVR.

Received: May 18, 2017
Accepted: December 26, 2017
Correspondence to:
Tamara Jakimov
Department of Cardiology
Clinical and Hospital Center “Bežanijska Kosa”, Belgrade, Serbia

Igor Mrdović, Branka Filipović, Marija Zdravković, Aleksandra Djoković, Saša Hinić, Nataša Milić, Branislav Filipović
1Department of Cardiology, Clinical and Hospital Center “Bežanijska Kosa”, Belgrade, Serbia
2Emergency Center, Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
3Department of Gastroenterology, Clinical and Hospital Center “Bežanijska kosa” and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
4Department of Cardiology, Clinical and Hospital Center “Bežanijska kosa” and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
5Institute for Medical Statistics and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
6Institute of Anatomy “Niko Miljanic” and Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Tamara Jakimov, Igor Mrdović, Branka Filipović, Marija Zdravković, Aleksandra Djoković, Saša Hinić, Nataša Milić, Branislav Filipović
1Department of Cardiology, Clinical and Hospital Center “Bežanijska Kosa”, Belgrade, Serbia
2Emergency Center, Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
3Department of Gastroenterology, Clinical and Hospital Center “Bežanijska kosa” and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
4Department of Cardiology, Clinical and Hospital Center “Bežanijska kosa” and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
5Institute for Medical Statistics and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
6Institute of Anatomy “Niko Miljanic” and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Variations in clinical appearance and outcome in patients with acute coronary syndrome (ACS) require a reliable method of risk assessment for further major adverse cardiac events (MACE) during the ACS treatment. Risk stratification is a useful tool for planning early treatment, discharge, and rehabilitation of ASC patients, performing research after ACS, and expediting the definitive decision about further treatment (1,2).

Different scores are in use for the estimation of ACS outcome. Thrombolysis in myocardial infarction (TIMI) is a simple bedside score that predicts 30-day mortality in patients with ST-elevation myocardial infarction (STEMI). Also, the TIMI score evaluates 14-day adverse events in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI). Several studies confirmed the efficacy of this index in the prognosis of mortality within 30-day period, although some attenuation was shown for patients older than 65 years (3-6). However, the TIMI score was based on clinical studies including selected populations of patients with low comorbidity rates and it does not always reflect the reality in clinical practice.

Global registry for acute coronary events (GRACE) score demonstrated its superiority in the assessment of 6-months mortality risk (7,8). Unlike TIMI, the GRACE score was derived from the Global Registry of Acute Coronary Syndrome data. As it was based on a wider sample of unselected population (9), it is more reliable for the routine clinical use. Several international reports compared the GRACE score with the TIMI score, showing that the GRACE score was a better predictor of clinical outcome than the TIMI score (10,11).

Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention (RISK-PCI score) was developed to predict 30-day MACE, such as non-fatal REMI, death, and cerebrovascular insult, in patients with STEMI after percutaneous coronary intervention (PCI) (12). The definitive value of all the scores is influenced by various clinical factors, such as score variables, period of the score evaluation, patient population, and analyzed adverse cardiovascular outcomes. RISK-PCI score has not been tested in patients with UA/NSTEMI. Although the GRACE score has already been established as the score of choice for the risk estimation (13), RISK-PCI also seems to be reliable considering that it includes clinical, laboratory, and diagnostic parameters. Our hypothesis was that the RISK-PCI score was as accurate as the GRACE and TIMI scores in predicting a composite MACE in patients with UA/NSTEMI.

The aim of our study was to estimate the prognostic potential of the RISK-PCI score and compare it with GRACE and TIMI scores for prediction of composite MACE occurrence within 30 days of a patient’s presentation with ACS.

METHODS

Patients

This single-center retrospective study included 200 patients with signs and symptoms compatible with ACS who were admitted to hospital between January 2014 and July 2014. There were 140 men and 60 women, with the mean age (±standard deviation, SD) of 62.3 ± 10.8 years (Table 1). The signs and symptoms compatible with ACS were acute chest pain or equivalent, and/or increase of cardiac troponin over the upper reference limit, and/or new significant ST-segment–T wave (ST–T) changes or new left bundle branch block (LBBB) in electrocardiogram (ECG), and/or images showing loss of viable myocardium or regional contractile abnormality (14). Clinical data, including previous medical history and risk factors, were taken into consideration.

Exclusion criteria were refusal to give consent for invasive treatment, active or recent internal bleeding, history of bleeding after non-steroid anti-inflammatory agents, known bleeding diathesis, intracerebral mass or aneurysm, intolerance or allergy to acetylsalicylates or clopidogrel, history of hypersensitivity to iodinated contrast media, cardiogenic shock at admission, non-cardiac conditions that could interfere with compliance with the protocol or necessitate interruption of the treatment with thienopyridines, and coexisting conditions associated with a limited life expectancy at 30-day follow-up. Revascularization procedure was performed in all patients in accordance with the applicable clinical practice guidelines for PCI (15). Before PCI, patients had been administered anticoagulant therapy and a loading dose of acetylsalicylates and clopidogrel. All patients were informed in detail about the intervention procedure and all signed a written consent.

Primary PCI was performed via femoral approach, using standard 6F or 7F guiding catheters. The procedure began with a visualization of the non-infarction related artery (IRA), followed by the visualization of the IRA. Stenting was performed in patients with anatomically-suitable artery with a diameter of ≥2.0 mm and without excessive tortuosity and extremely angulated lesions. Angioplasty without stenting was performed on selected pa-
tients who were candidates for urgent surgery or patients with small and tortuous or highly calcified IRA. Drug-eluting stents (DES) were suggested for selected patients with in-stent restenosis, diabetes mellitus, very long lesions, or bifurcated lesions. The decision about DES implantation was left to the discretion of the surgeon. In our trial, manual aspiration was used sporadically and was not included in the final analysis. Flow grades were assessed according to the TIMI criteria. Temporary pacemaker was placed in all patients with high-grade atrioventricular (AV) block or bradycardia and hemodynamic compromise.

After PCI, dual antiplatelet therapy was prescribed for 12 months to all patients included in the study.

**TABLE 1.** Baseline demographic, clinical, angiographic, and procedural characteristics of the patients with acute coronary syndrome*

| Patient characteristics | ACS total (N = 200) | NSTEMI (N = 69) | UA (N = 15) | STEMI (N = 116) |
|-------------------------|---------------------|----------------|-----------|----------------|
| Age (years, mean±SD)    | 62.3 ± 10.8         | 63.3 ± 10.4    | 61.4 ± 11.1 |
| Sex (men/women)         | 140/60              | 55/29          | 85/31     |
| Medical history         |                     |                |           |                |
| prior MI                | 40 (20.0)           | 25 (29.8)      | 15 (12.9) |
| prior AP                | 151 (75.5)          | 76 (90.5)      | 75 (64.6) |
| prior CHF               | 39 (19.5)           | 26 (31.0)      | 13 (11.2) |
| anterior MI             | 57 (28.5)           | 23 (27.4)      | 34 (29.3) |
| dyslipidemia            | 174 (87.0)          | 74 (88.1)      | 100 (86.2) |
| >3 standard risk factors| 140 (70.0)          | 66 (78.6)      | 74 (63.8) |
| hypertension            | 130 (65.0)          | 63 (75.0)      | 67 (57.8) |
| diabetes mellitus       | 26 (13.0)           | 10 (11.9)      | 16 (13.8) |
| current smokers         | 112 (56.0)          | 41 (48.8)      | 70 (60.3) |
| Clinical characteristics |                     |                |           |                |
| KILLIP† class I         | 156 (78.0)          | 62 (73.8)      | 94 (81.0) |
| KILLIP† class II        | 41 (20.5)           | 20 (23.8)      | 21 (18.1) |
| KILLIP† class III       | 3 (1.5)             | 2 (2.4)        | 1 (0.9)   |
| asystoly                | 5 (2.5)             | 0 (0.0)        | 5 (4.3)   |
| ST elevation            | 116 (58.0)          | 0 (0.0)        | 116 (100.0) |
| ST depression           | 117 (58.5)          | 55 (65.5)      | 62 (53.4) |
| AVB III                 | 4 (2.0)             | 0 (0.0)        | 4 (3.4)   |
| ABBB                    | 10 (5.0)            | 3 (3.6)        | 7 (6.0)   |
| heart rate (beats/min, median with interquartile range) | 80.0 (40.0-300.0) | 80.0 (47.0-120.0) | 78.5 (40.0-300.0) |
| SBP (mmHg, median with interquartile range)         | 140.0 (50.0-220.0) | 150.0 (90.0-220.0) | 135.0 (50.0-220.0) |
| LVEF (% median with interquartile range)            | 45.0 (5.0-66.0)    | 45.0 (15.0-65.0) | 45.0 (5.0-66.0) |
| Laboratory data on admission                           |                |                |           |
| leukocyte count (x 10^9/L, median with interquartile range) | 9.9 (4.4-28.9)  | 9.5 (4.4-22.5) | 10.4 (4.7-28.9) |
| glucose (mmol/L, median with interquartile range)    | 7.7 (3.6-53.6)     | 7.2 (4.1-23.0) | 8.2 (3.6-53.6) |
| creatinine (mmol/L, median with interquartile range) | 104.0 (56.4-148.8) | 104.5 (70.1-152.0) | 103.9 (56.4-1488.0) |
| creatinine clearance (mL/min, median with interquartile range) | 69.9 (29.8-171.9) | 66.0 (29.8-138.3) | 71.8 (30.9-171.9) |
| peak troponin I (µg/L, median with interquartile range) | 0.8 (0.0-50.0) | 0.5 (0.0-11.2) | 1.6 (0.0-50.0) |
| Angiographic findings                                      |                |                |           |
| diameter of IRAs<2.5 mm (median with interquartile range) | 24 (12.0)   | 11 (13.1)      | 13 (11.2) |
| pre-procedural TIMI flow 0                                | 78 (39.0)       | 13 (15.5)      | 65 (56.0) |
| final TIMI flow grade <3                                  | 63 (31.5)       | 32 (38.1)      | 31 (26.7) |
| temporary pacemaker                                       | 4 (2.0)         | 0 (0.0)        | 4 (3.4)   |

*Abbreviations: ACS – acute coronary syndrome; NSTEMI – non-ST elevation myocardial infarction; UA – unstable angina; STEMI – ST elevation myocardial infarction; SD – standard deviation; MI – myocardial infarction; AP – angina pectoris; CHF – congestive heart failure; AVB III – atrioventricular block grade III; ABBB – acute bundle branch block; SBP – systolic blood pressure; LVEF – left ventricular ejection fraction; IRA – infarction-related artery; CABG – coronary artery bypass grafting.

†KILLIP – classification of the severity of heart failure by Thomas Killip: class I – no heart failure; class II - heart failure, diagnostic criteria include rales, S3 gallop, and venous hypertension; class III – pulmonary edema; class IV – cardiogenic shock.

www.cmj.hr
Method

The primary endpoint was a composite 30-day MACE consisting of death, target-vessel revascularization (TVR), stroke, and non-fatal recurrent myocardial infarction (REMI). TVR was defined as ischemia-driven revascularization of the IRA during a follow-up period (16). Stroke was defined as a new onset of focal or global neurological deficit lasting more than 24 hours. The presence of recurrent ischemic symptoms for 20 minutes or longer, recurrence of ST-segment deflection, T wave inversion or new pathognomonic Q waves in at least two contiguous leads, and increase in cardiac troponin above the upper reference limit and over 20% of the lowest recovery level from the index myocardial infarction (MI) were considered as REMI (14).

A planned staged PCI was not considered a TVR. All patients were followed up for 30 days or until death, whichever occurred first. Follow-up data were obtained in scheduled telephone interviews and outpatient visits. No patient was lost to follow-up.

Four scores computed from the previously acquired data included TIMI score, GRACE score on admission, GRACE score on discharge, and RISK-PCI score.

The TIMI score for NSTEMI and UA involves patient age, risk factors for coronary artery disease (hypertension, dyslipidemia, diabetes mellitus, active smoking, and heredity for coronary disease), prior coronary stenosis of 50% or more, use of acetylsalicylates in the previous seven days, at least 2 angina events in the previous 24 hours, increased serum cardiac biomarkers, and ST-segment deviation on ECG at presentation. The score of seven points is an important predictor of the development of adverse events such as new MI or REMI, death or severe recurrent ischemia requiring urgent revascularization (17). The TIMI score for STEMI involves patient age, systolic blood pressure value, heart failure, body mass,
anterior MI or left bundle branch block, presence of diabetes mellitus, hypertension or angina pectoris, and the period between the symptom onset and the beginning of treatment (18).

The GRACE score on admission includes patient age, heart rate, systolic blood pressure value, increased laboratory cardiac markers and serum creatinine level, and ST deviation or asystole on ECG (7). The GRACE score on discharge includes patient age, aforementioned clinical signs and laboratory parameters, ST depression on ECG, prior MI, and in-hospital coronary intervention (19). The GRACE ACS risk calculators are available online (20).

The RISK-PCI score includes 12 variables as follows: patient age, prior MI, anterior MI, acute bundle branch block and high-grade AV block, laboratory findings (leukocyte counts, glycemia, and creatinine clearance), echocardiographic evaluation of left ventricular ejection fraction (EF), angiographic assessment of the IRA diameter, and initial and post-procedural TIMI flow grade. The total score ranges from 0 to 20. Patients with 5-6.5 score are at high risk (12).

Statistical analysis

Statistical analysis was performed using a commercially available statistical software program (SPSS 13.0, Inc, Chicago IL, US). Normality of data distribution was assessed using Smirnov-Kolmogorov test. In addition to the usual parameters of central tendency (mean with standard deviation [SD]), Student’s t test was applied to test for differences between two related samples. For the non-parametric data, analysis was performed using the Mann-Whitney test, receiver operating characteristic (ROC) curve, and univariate and multivariate logistic regression analysis. The discrimination of the model was analyzed by calculating the area under the curve (AUC), which represented the accuracy of each value in discriminating high from low risk for patients with adverse events. AUC≥0.90 was defined as ‘excellent’, AUC≥0.70 was ‘good’, and AUC<0.70 was considered ‘inadequate’ (21). Calibration was evaluated by the Hosmer-Lemeshow goodness-of-fit test. The probability level in all tests was set at 95%.

RESULTS

Of 200 ACS patients included in the study, STEMI was diagnosed in 116 (58.0%), NSTEMI in 69 (34.5%), and UA in 15 (7.5%) patients (Figure 1).

Incidence of clinical events

The primary composite endpoint MACE occurred in 17 patients (8.5%) during the 30-day follow-up period including death in six cases (3.0%), REMI in two cases (1.0%), and urgent myocardial revascularizations due to current ischemia in 10 cases (5.2%). One patient had two undesired effects, reinfarction and subsequent fatal outcome. No stroke occurred during the follow-up period. Of the total of 200 patients, 122 (61.0%) underwent PCI and 13 (6.5%) underwent coronary artery bypass grafting (CAGB) in the same period. Four patients (2%) died in the hospital. The cause of death of three patients was the progression of heart failure and one patient had a fatal REMI. None of the patients used mechanical circulatory assistance while hospitalized. Two patients died after discharge from hospital within 20 days.

Risk model calibration and discrimination

The RISK-PCI score expressed an excellent predictive potential for 30-day MACE (AUC=0.94; 95% CI 1.790-4.353; P<0.001) in comparison with the GRACE scores on admis-
sion (AUC = 0.73; 95% CI 1.013-1.045; P = 0.002) and discharge (AUC = 0.65; 95% CI 1.000-1.033; P = 0.035; Figure 2). The RISK-PCI score was the only score that could point toward TVR (AUC = 0.91; 95% CI 1.392-2.882; P < 0.001; Figure 3). The RISK-PCI score and GRACE scores on admission and discharge showed good discrimination performance for death within 30 days of admission. The RISK-PCI score demonstrated an excellent discriminative potential for 30-day death (AUC = 0.96; 95% CI 1.339-3.548; P < 0.001) in comparison with the GRACE score on admission (AUC = 0.88; 95% CI 1.018-1.072; P = 0.002) and discharge (AUC = 0.78; 95% CI 1.000-1.058; P = 0.021; Figure 4).

The TIMI score did not show any statistical significance in 30-day prediction of death (AUC = 0.64; 95% CI 0.935-2.156; P > 0.05), repeated urgent myocardial revascularization (AUC = 0.49; 95% CI 0.728-1.382; P > 0.05) or composite MACE (AUC = 0.56; 95% CI 0.904-1.490; P > 0.05).

The Hosmer-Lemeshow P values for all subgroups were >0.05, suggesting a good model fit (Table 2).

The logistic regression showed that the RISK-PCI score was an important predictor of death, urgent revascularization, and composite MACE, whereas the GRACE score on admission was adequate for predicting death and composite MACE.

### TABLE 2. Hosmer-Lemeshow calibration statistics for RISK-PCI, GRACE, and TIMI risk scores in patients with acute coronary syndrome

| Risk score     | Death χ² | Death P | TVR χ² | TVR P | MACE χ² | MACE P |
|----------------|----------|---------|--------|-------|--------|-------|
| RISK-PCI       | 0.851    | 0.997   | 3.509  | 0.834 | 2.527  | 0.922 |
| GRACE on admission | 2.156 | 0.976   | 4.319  | 0.827 | 4.540  | 0.805 |
| GRACE on discharge | 13.796 | 0.087   | 5.786  | 0.671 | 5.990  | 0.648 |
| TIMI           | 6.605    | 0.252   | 2.499  | 0.777 | 3.046  | 0.693 |

*Abbreviations: TVR – target-vessel revascularization; MACE – major adverse cardiac events; RISK-PCI – predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention; GRACE – Global Registry for Acute Coronary Events; TIMI – thrombolyisis in myocardial infarction.
also showed a good prognostic value for the adverse cardiovascular events after primary percutaneous coronary intervention; GRACE - Global Registry for Acute Coronary Events; TIMI – thrombolysis in myocardial infarction; CI – confidence intervals; RR – relative risk.

**TABLE 3. Results of the univariable and multivariable logistic regression analyses for the RISK-PCI, GRACE, and TIMI scoring models***

| Risk score         | Death univariate | TVR univariate | MACE univariate | MACE multivariate |
|--------------------|-----------------|----------------|-----------------|-------------------|
| **RR (95% CI for RR)** | **P**        | **RR (95% CI for RR)** | **P**      | **RR (95% CI for RR)** | **P** |
| RISK PCI on admission | 0.002         | 2.180 (1.339-3.548) | <0.001       | 2.003 (1.392-2.882) | <0.001 |
| GRACE on admission  | 0.001         | 1.045 (1.018-1.072) | 0.395       | 1.008 (0.989-1.028) | <0.001 |
| GRACE on discharge  | 0.047         | 1.029 (1.000-1.058) | 0.538       | 1.006 (0.986-1.027) | 0.058  |
| TIMI                | 0.100         | 1.420 (0.935-2.156) | 0.987       | 1.003 (0.728-1.382) | 0.243  |

*Abbreviations: TVR – target-vessel revascularization; MACE – major adverse cardiac events; RISK-PCI – the score predicting 30-day major adverse cardiovascular events; GRACE – Global Registry for Acute Coronary Events; TIMI – thrombolysis in myocardial infarction; CI – confidence intervals; RR – relative risk.

**DISCUSSION**

This study was the first to compare different clinical scores, GRACE, TIMI, and newly introduced RISK-PCI, for their ability to predict possible adverse cardiovascular outcome in 30-day follow-up period (2,7,12,16). The RISK-PCI score reliably predicted a 30-day MACE in ACS patients and was non-inferior to the other two clinical scores. The most important advantage of RISK-PCI score was a prediction of TVR.

According to our results, the TIMI score was found to have the worst predictive potential, probably due to a relatively small number of parameters used, i.e., symptom of the acute renal failure, generally accepted as an independent predictor of the poor in-hospital survival, was not considered at all (22,23). Nevertheless, the TIMI score seemed to be useful for a quick evaluation of ACS patients during the emergency department visit (24). The GRACE risk score had the highest prognostic accuracy for long-term mortality at each observed time point. The GRACE risk score is unique, because it is based on a large registry of patients across the entire spectrum of coronary syndromes and designed for the prognosis of all-cause mortality at six months (19,25). Furthermore, the GRACE score seems to be the most suitable for the prediction over a longer follow-up period (25). In our study, the RISK-PCI and GRACE scores on admission and discharge showed a good discriminative potential regarding the patient stratification into low- and high-risk groups. These two scoring systems also showed a good prognostic value for the adverse cardiovascular events in 30-day follow-up period. Specifically, every third patient with the RISK-PCI score ≥7 (very high-risk group) died during the 30-day follow-up, which implies that such patients need close monitoring during the acute phase of MI and careful evaluation of the dual antiplatelet therapy. Moreover, the high-risk patients might also be candidates for complete revascularization before discharge from hospital (12). The RISK-PCI score was found to be the most precise for the prediction of major cardiovascular adverse events, such as death or relevant ischemia requiring urgent revascularization. The RISK-PCI scoring system had the best predictive value for the MACE estimation, with a good predictive ability, which is not surprising considering that RISK-PCI was designed for the MACE anticipation from the beginning. On the other hand, the GRACE scoring system was not initially intended for the MACE estimation, but it has been gradually used for the prediction of other adverse incidents during in-hospital stay, such as re-infarction, arrhythmias, acute congestive heart failure, shock, and cerebrovascular incidents (26,27). Prognostic information based exclusively on the ECG changes and cardiac markers is insufficient, because ECG changes have high specificity but low sensitivity for the myocardial ischemia. Furthermore, prognostic potential of the cardiac markers is attenuated due to the period of latency between the moment of cardiac myocyte necrosis and subsequent entrance of the markers into the circulation. Therefore, in the emergency department, risk indices are more favorable for the prognosis in comparison with ECG findings and troponin concentration (11,28). In recent studies, acute branch block (29,30), post-interventional TIMI flow through the IRA (31,32), and left ventricle ejection fraction (31,33) were found prognostically important for long-term outcome. Furthermore, an anterior wall MI was associated with a significantly higher risk of mortality than an inferior wall MI. Renal insufficiency and age were emphasized as good MACE predictors (32-36). All these variables are included in the RISK-PCI score and this fact probably increases its predictive accuracy. Leukocyte count on admission makes the crucial difference between RISK-PCI and other two scoring systems, because its increased value positively correlates with lower subepicardial flow, frequent left chamber remodeling, congestive...
heart failure, and fatal outcome (37). Angiographic parameters are omitted from the GRACE score on admission and the TIMI score, while GRACE score on discharge takes into consideration only two similar variables, prior MI and eventful PCI performance (8). In the RISK-PCI score, angiographic assessment of the diameter of the infarction-related coronary artery and its TIMI flow are considered as the factor for the overall evaluation of the patient’s condition and subsequent selection on the basis of the seriousness of the symptoms. We found the RISK-PCI score to be an independent predictor of death, urgent revascularization, and composite MACE, and the GRACE score on admission to be an independent predictor of the fatal outcome after the 30-day follow-up period.

The main limitation of our study lies in its retrospective and single-center-based design. In consistency with the widely accepted risk models for primary PCI, patients with cardiogenic shock at presentation were excluded from the trial. These patients by definition fall into the highest-risk category and their treatment differs from the overall primary PCI population in terms of the time window for revascularization (no time limit) and the extent of revascularization (complete revascularization recommended). We performed only femoral approach in the aforementioned period. Therefore, our results do not refer to the radial approach.

Given a relatively small number of patients in our study, the results of the study should be considered as hypothesis-generating and further verified in a larger trial in future.

In conclusion, RISK-PCI showed a reasonably fair discriminative ability for the 30-day MACE in ACS patients. In comparison with the GRACE and TIMI scores, the RISK-PCI score showed a non-inferior ability to predict 30-day MACE and death and was the only index that could predict recurrent ischemia requiring TVR. Further research in larger patient cohorts is needed for the clinical validation of RISK-PCI score in patients with UA/NSTEMI.

Acknowledgment The authors express their gratitude to physicians and nurses of the Clinical and Hospital Center “Belizeanska kosa’ Coronary unit and Catheterization laboratory participating in the trial.

Funding The study was supported by the grant II 41020, Ministry of Education, Science and Technological Development Republic of Serbia.

Ethical approval received from the Ethic Committee (registration code 8314/14) of Clinical and Hospital Center “Belizeanska kosa”, Belgrade, Serbia.

Declaration of authorship TJ and IM conceived the study and participated in its design, acquisition of data, and coordination. TJ, MZ, AD, and SH participated in the acquisition of data. NM and BF performed statistical analysis. TJ, BF, and IM drafted the manuscript. NM, TJ, and IM participated in the analysis and interpretation of data. All authors contributed ideas for discussion, drafted and reviewed the manuscript, and approved the final version.

Competing interests All authors have completed the Unified Competing Interest form at www.cmj.org/iccm_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1. Collinson J, Flather MD, Fox KA, Findlay I, Rodrigues E, Dooley P, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAS/UK). Eur Heart J. 2000;21:1450-7. Medline:10952837 doi:10.1053/ehj.1999.1995
2. Hills LD, Lange RA. Optimal management acute coronary syndromes. N Engl J Med. 2009;360:2237-40. Medline:19458369 doi:10.1056/NEJMoa0902632
3. Antman EM, TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: A double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Am Hear J. 1998;135:S53-60. Medline:9628449 doi:10.1016/S0002-9378(98)070265-0
4. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin in non-Q-wave coronary events. Am J Cardiol. 1998;82 SB:19L-24L. Medline:9737476 doi:10.1016/S0002-9149(98)00108-8
5. Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, DiBattiste PM, et al. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Hear J. 2005;149:846-50. Medline:1594966 doi:10.1016/j.ahj.2004.08.042
6. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tiropiban: rationale and study design of the International TACTICS-TIMI 18 trial. Am J Cardiol. 1998;82:731-6. Medline:9761082 doi:10.1016/S0002-9149(98)000540-2
7. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med. 2003;163:2345-53. Medline:14581255 doi:10.1001/archinte.163.19.2345
8. Tang EW, Wong CK, Heribison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Hear J. 2007;153:29-35. Medline:17714633 doi:10.1016/j.ahj.2006.10.004
10 de Araújo Gonçalves P, Ferreira J, Aguiar C, Seabra-Gomes R, TIMI, PURSUIT, and TIMI risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005;26:865-72. Medline:15764619 doi:10.1093/eurheartj/ehi187

11 Ramsay G, Podgordzka M, McClure C, Fox KA. Risk prediction in patients presenting with suspected cardiac pain: the GRACE and TIMI risk scores versus clinical evaluation. QJM. 2007;100:11-8. Medline:17175559 doi:10.1093/qmj/hcl133

12 Mrdović I, Savić l, Krijanac G, Asanin M, Peruničić J, Jasica R, et al. Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI score. Int J Cardiol. 2013;162:220-7. Medline:21663982 doi:10.1016/j.ijcard.2011.05.071

13 Roffi M, Carlo P, Jean PC, Christian M, Marco V, Felicita A, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:267-315. Medline:26330110 doi:10.1093/eurheartj/ehs320

14 Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-67. Medline:22924214 doi:10.1093/eurheartj/ehs184

15 Windedeck S, Kolb P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial Revascularization: Tasc Force; on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619. Medline:25173339 doi:10.1093/eurheartj/ehu278

16 Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51. Medline:17470709 doi:10.1161/CIRCULATIONAHA.106.685313

17 Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papaichis G, et al. The TIMI risk score for unstable angina/non-ST-elevation MI. A method for prognostication and therapeutic decision making. JAMA. 2000;284:835-42. Medline:10938172 doi:10.1001/jama.284.7.835

18 Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous rPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031-7. Medline:11044416 doi:10.1161/01.CIR.102.17.2031

19 Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post discharge death in an international registry. JAMA. 2004;291:2727-33. Medline:15187054 doi:10.1001/jama.291.22.2727

20 Methods and formulas used to calculate the GRACE Risk Scores for patients presenting to hospital with acute coronary syndromes. Center for Outcomes Research, University of Massachusetts Medical School. Available from: https://www.outcomes.umassmed.org/grace/. Accessed: May 18, 2016.

21 Novotny N. Clinical prediction model of medical inpatients at risk of 19 early readmission: development and validation. [Internet] Dissertation. University of Chicago (IL); 2008. Available from: http://gradworks.proquest.com/33/27/3327513.html. Accessed: May 18, 2016.

22 Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-80. Medline:12186803 doi:10.1161/01.CIR.0000027560.41358.B3

23 Santopinto JJ, Fox KA, Goldberg Budaj A, Pirier G, Avezum A, Guiba D, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003;89:1003-8. Medline:1293009 doi:10.1136/heart.89.10.1003

24 Hess EP, Aqurwal D, Chandra S, Murad MH, Erwin PJ, Hollander JE, et al. Diagnostic accuracy of the TIMI risk score in patients with chest pain in the emergency department: a meta-analysis. CMAJ. 2010;182:1039-44. Medline:20530163 doi:10.1503/cmaj.092119

25 Littnerova S, Kala P, Jarkovsky J, Kubkova l, Prymusova K, Kubena P, et al. GRACE Score among six risk scoring systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) demonstrated the best predictive value for prediction of long-term mortality in patients with ST-elevation myocardial infarction. PLoS One. 2015;10:e0123215. Medline:25893501 doi:10.1371/journal.pone.0123215

26 Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333:1091-4. Medline:17032691 doi:10.1136/bmj.38985.646481.55

27 Brieger D, Fox KA, Fitzgerald G, Eagle KA, Budaj A, Avezum A, et al; Global Registry of Acute Coronary Events Investigators. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart.
28 Ramjane K, Han L, Jin C. The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention. Exp Clin Cardiol. 2008;13:121-8. Medline:19343126

29 Go AS, Barron HV, Rundle AC, Ornato JP, Avins AL. Bundle-branch block and in-hospital mortality in acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. Ann Intern Med. 1998;129:90-7. Medline:9841600 doi:10.7326/0003-4819-129-9-199811010-00003

30 Addalla S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB, et al. Predicting mortality in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). Am J Cardiol. 2004;93:629-32. Medline:14996596 doi:10.1016/j.amjcard.2004.06.065

31 Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, et al. Prediction of mortality after primary percutaneous intervention for acute myocardial infarction. The CADILLAC risk score. J Am Coll Cardiol. 2005;45:1397-405. Medline:15862409 doi:10.1016/j.jacc.2005.01.041

32 Heggunje PS, Harjai KJ, Stone GW, Mehta RH, Marsalese DL, Boura JA, et al. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1400-7. Medline:15464319 doi:10.1016/j.jacc.2004.06.065

33 Califf RM, Pieper KS, Lee KL, Van De Werf F, Simes RJ, Armstrong PW, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in Global Utilization of Streptokinase and t-PA for Occluded coronary Arteries trial. Circulation. 2000;101:2231-8. Medline:10811588 doi:10.1161/01.CIR.101.19.2231

34 Gomez JF, Zareba W, Moss AJ, McNitt S, Hall WJ. Prognostic value of location and type of myocardial infarction in the setting of advanced left ventricular dysfunction. Am J Cardiol. 2007;99:642-6. Medline:17317364 doi:10.1016/j.amjcard.2006.10.021

35 Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95. Medline:15385655 doi:10.1056/NEJMoa041365

36 Rosengren A, Wallentin L, Simoons A, Gitt AK, Behar S, Battler A, et al. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. Eur Heart J. 2006;27:789-95. Medline:16644911 doi:10.1093/eurheartj/ehi774

37 Mariani M, Fetteau R, Rossetti E, Poli A, Poletti F, Vandoni P, et al. Significance of total and differential leukocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty. Eur Heart J. 2006;27:2511-5. Medline:16923741 doi:10.1093/eurheartj/ehi191